Evaluation of axillary lymph nodes response after neoadjuvant chemotherapy in locally advanced breast cancer

王玉洁; 柳光宇

doi:10.3969/j.issn.1007-3969.2015.08.012

您当前的位置：

首页 >

文章列表页 >

Evaluation of axillary lymph nodes response after neoadjuvant chemotherapy in locally advanced breast cancer

更新时间：2025-12-31

- Evaluation of axillary lymph nodes response after neoadjuvant chemotherapy in locally advanced breast cancer
- China Oncology Vol. 25, Issue 8, Pages: 629-634(2015)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.08.012
  CLC：
- Published Online：14 December 2015，
  
  Published：14 December 2015
- 稿件说明：
移动端阅览
王玉洁,柳光宇. 乳腺癌新辅助化疗后腋窝淋巴结状态的评估[J]. 中国癌症杂志, 2015, 25(8): 629-634.

王玉洁, 柳光宇. Evaluation of axillary lymph nodes response after neoadjuvant chemotherapy in locally advanced breast cancer[J]. China Oncology, 2015, 25(8): 629-634.
王玉洁,柳光宇. 乳腺癌新辅助化疗后腋窝淋巴结状态的评估[J]. 中国癌症杂志, 2015, 25(8): 629-634. DOI： 10.3969/j.issn.1007-3969.2015.08.012.

王玉洁, 柳光宇. Evaluation of axillary lymph nodes response after neoadjuvant chemotherapy in locally advanced breast cancer[J]. China Oncology, 2015, 25(8): 629-634. DOI： 10.3969/j.issn.1007-3969.2015.08.012.

摘要

新辅助化疗或新辅助化疗联合生物靶向治疗日趋成为局部晚期乳腺癌(Ⅱb~Ⅲ)的标准治疗方式，除了能降低原发肿块的临床分期，约有40%的患者能达到腋窝淋巴结的病理完全缓解，从而实现了腋窝淋巴结的降期。而对于经过新辅助化疗或化疗联合靶向治疗后经影像学评估达到腋窝淋巴结临床完全缓解的患者，其腋窝淋巴结缓解情况的预测及新辅助化疗后腋窝前哨淋巴结活检等，仍存在诸多争议，成为临床治疗选择上的难题。本文拟对近年来新辅助化疗后腋窝淋巴结处理的相关研究及临床试验进行分析和解读，并对新近开展的临床研究进行梳理，以期为临床提供更多参考信息。

Abstract

Neoadjuvant chemotherapy or neoadjuvant chemotherapy in combination with targeted therapy has been widely accepted as the standard treatment for locally advanced breast cancer (Ⅱb-Ⅲ). Nearly forty percent of the patients who accepted neoadjuvant chemotherapy achieved pathological complete response of axillary lymph nodes in addition to downstage the primary lesions. However

for patients with clinical complete response of lymph nodes after pre-operative systemic therapy

there are constant controversies regarding the prediction of axillary lymph nodes response and sentinel lymph nodes biopsy after the treatment. Here we design to review the latest studies about how to evaluate the axillary lymph nodes response after neoadjuvant chemotherapy and try to enlighten the treatment choices in clinical practice.

关键词

Keywords

references

Views

2064

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective study on regional lymph node radiotherapy after axillary dissection exemption in breast cancer patients with sentinel lymph node positive status

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy

Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer

Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer

Validation and modification study of axillary node pathologic complete response predictive model after neoadjuvant chemotherapy for breast cancer

Related Author

Pengfei QIU

Yongsheng WANG

Tong LI

Zhiqiang SHI

Yongjin LU

Qun ZHAO

Yang LIU

Yong LI

Related Institution

Jinan Fourth People’s Hospital, Third Affiliated Hospital of Shandong First Medical University

Shandong First Medical University Affiliated Cancer Hospital (Shandong Cancer Prevention and Treatment Research Institute, Shandong Cancer Hospital)

Shandong First Medical University (Shandong Academy of Medical Sciences)

Department of the Third General Surgery, Fourth Hospital of Hebei Medical University

Pathology Department, Fourth Hospital of Hebei Medical University

AI问答

⁰